Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) (B-Sure)
A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study
Sponsor: GlaxoSmithKline
Listed as NCT04954859, this PHASE2 trial focuses on Hepatitis B and remains actively recruiting participants. Sponsored by GlaxoSmithKline, it has been updated 12 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Dec 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — May 2022 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .